Alvotech
在场
Alvotech 的所有者是 Alvogen.
Alvogen 在 4 个国家有直接业务。
Alvogen 拥有 5家子公司，其中包括 Adalvo、Alvogen Americas 和 Alvogen APAC。
他们在：
涉及Alvogen的并购和融资。
- Alvotech 刚刚宣布为 100 筹款数百万美元。 (公布2023八月2号).
- Alvotech 刚刚宣布为 70 筹款数百万美元。 (公布2022十二月20号).
高管
查看带有其 27 名主要高管的组织结构图
Alvotech 搜索最多的简介
- Robert Wessman, Executive Chairman and Chief Executive Officer
- Arni Hardarson, Independent Director
- Ann Merchant, Independent Director
高管在Alvotech变化
- Hjörleifur Pálsson已作为Director加入公司 (新闻发布的2024六月13号).
- Christina Siniscalchi已作为Interim Chief Quality Officer加入公司 (新闻发布的2024三月1号).
创建提醒
跟踪 Alvotech 的高管变动
生物技术
Alvogen 拥有 2,327 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Chromocell的新名称是Channel Therapeutics Corporation。 (公布2024十一月22号).
- Enveda Biosciences 刚刚宣布为 130 筹款数百万美元。 (公布2024十一月22号).
- Alentis Therapeutics 刚刚宣布为 181 筹款数百万美元。 (公布2024十一月20号).
生物技术 行业的其他推荐联系人
消息
Alvotech 的最新新闻稿
- Alvotech Reports Financial Results for the First Nine Months of 2024 | Alvotech
- Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024 | Alvotech
- European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab) | Alvotech
- Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET | Alvotech
- Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab) | Alvotech
- Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024 | Alvotech
- Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024 | Alvotech
- Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab) | Alvotech
- European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva® | Alvotech
- Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio® | Alvotech
- View more press releases Close
通过电子邮件
